Adamas Pharmaceuticals Inc. (ADMS)

6.25
NASDAQ : Health Technology
Prev Close 6.53
Day Low/High 6.21 / 6.66
52 Wk Low/High 3.35 / 12.57
Avg Volume 573.70K
Exchange NASDAQ
Shares Outstanding 27.86M
Market Cap 184.42M
EPS -4.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Playing Biotech After FDA Approval

Playing Biotech After FDA Approval

Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Winning FDA approval isn't always a win.

Winning FDA Approval Isn't Always a Win

Winning FDA Approval Isn't Always a Win

The experiences of three biotechs show how drug approvals don't always translate into stock gains.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

Hurricane Harvey, Now a Category 2, Heads for Oil-Rich Gulf Coast

Hurricane Harvey, Now a Category 2, Heads for Oil-Rich Gulf Coast

Hurricane Harvey was upgraded to a category 2 storm overnight and could be a category 3 before the day is over.

3 Biotechs to Buy This Summer

3 Biotechs to Buy This Summer

These companies will do well, despite a range bound sector.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

Fitting Finish to a Tough Year

Fitting Finish to a Tough Year

Today's action was disappointing and frustrating.